Windward Bio: Drug Development Company Raises $200 Million (Series A)
By Amit Chowdhry ● Jan 13, 2025
Novo Holdings, a leading life science investor, announced that it has invested in a $200 million Series A launch financing for Windward Bio. This oversubscribed Series A launch financing was co-led by OrbiMed, Novo Holdings and Blue Owl Healthcare Opportunities, and joined by SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners.